99久久精品免费观看国产,色网站免费,2021国内精品久久久久久影院,国产免费福利网站,欧美日韩国产精品综合,国内在线精品,国产三级日本三级日产三

CN / EN

News

Technoderma Medicines Receives FDA Approval for Its Atopic Dermatitis Drug IND

Release time: 2022-08-09 Article source: 特科羅

On Aug 9th, 2022, US Pacific Time, Technoderma Medicines (TDM), a drug discovery startup specialized in dermatology indications based at Jiaxing,China, announced that FDA approved the IND application of its novel experimental drug for the topical treatment of Atopic Dermatitis (AD) by issuing a STUDY MAY PROCEED letter on Aug 1st, 2022. Phase I clinical trials will be carried out in several clinical sites in the US.


TDM-180935, TDM’s experimental drug approved in the IND application, is the first one out of several preclinical candidates from the company’s small molecule JAK inhibitor discovery program to enter clinical phase. Based on kinase, cellular and functional assays, TDM-180935 is a JAK1/TYK2 dual inhibitor.


Preclinical MoA studies revealed that TDM-180935 can potently inhibit Th2 immune response characteristic for the initiating phase of AD pathogenesis, as well as Th1 and Th17 immune responses that play a role during the chronic phase, thereby efficiently blocking all major pathogenic pathways leading to AD. The drug demonstrated dose-dependent efficacy on three mouse models for AD and a good safety profile as indicated by GLP toxicology studies.

TDM-180935 is the company’s second IND approval by FDA. Previously, TDM-105795, a small molecule thyroid hormone receptor agonist for the topical treatment of Androgenetic Alopecia (AGA) has been approved for phase I clinical trials in April 2021. Phase I trials of TDM-105795 will be completed in Q4 2022 and phase II trials are scheduled to start in Dec 2022 or Jan 2023.

金塔县| 清徐县| 青岛市| 清远市| 东莞市| 祥云县| 金湖县| 库尔勒市| 和林格尔县| 大石桥市| 朔州市| 贵港市| 剑河县| 武威市| 定襄县| 杭州市| 金山区| 略阳县| 如东县| 衡东县| 朝阳县| 张家川| 喀喇沁旗| 长治市| 玉环县| 策勒县| 玉树县| 诸城市| 无极县| 宜城市| 城固县| 方山县| 华容县| 佛教| 九龙坡区| 三江| 扎兰屯市| 阜阳市| 项城市| 龙川县| 弥勒县|